Publication | Closed Access

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Hematological MalignancyOpen-label TrialLymphoid NeoplasiaMedicineImmunologyPathologyGlobal Phase 3Cancer TreatmentImmunotherapyOncologyRadiation Oncology